| Assay ID | Title | Year | Journal | Article |
|---|
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6
| A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | | | |
| AID1224751 | Delta TM value showing the stabilisation of CAMK2A produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720163 | Millipore: Percentage of residual kinase activity of FLT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720475 | Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID524793 | Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay | 2009 | Nature chemical biology, Oct, Volume: 5, Issue:10
| Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. |
| AID266524 | Death of human SH-SY5Y cells in absence of 20 uM Q-VD-OPh by MTS reduction assay | 2006 | Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
| 3'-Substituted 7-halogenoindirubins, a new class of cell death inducing agents. |
| AID720048 | Millipore: Percentage of residual kinase activity of BLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720258 | Millipore: Percentage of residual kinase activity of MAPK14 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720182 | Millipore: Percentage of residual kinase activity of GSK3A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID618244 | Cytotoxicity against human NB39 cells assessed as cell viability after 48 hrs by MTT assay | 2011 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
| Synthesis of methoxy- and bromo-substituted indirubins and their activities on apoptosis induction in human neuroblastoma cells. |
| AID1139566 | Inhibition of human COX-2 using arachidonic acid at 10 uM after 5 mins by HPLC analysis | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID727167 | Inhibition of human recombinant CDK5 | 2013 | ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
| Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases. |
| AID720318 | Millipore: Percentage of residual kinase activity of MAPK8 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720161 | Millipore: Percentage of residual kinase activity of FGR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720176 | Millipore: Percentage of residual kinase activity of GRK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720238 | Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720357 | Millipore: Percentage of residual kinase activity of MAP2K7 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720093 | Millipore: Percentage of residual kinase activity of CSK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720334 | Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720395 | Millipore: Percentage of residual kinase activity of TSSK1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720367 | Millipore: Percentage of residual kinase activity of RPS6KA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720069 | Millipore: Percentage of residual kinase activity of CDK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720091 | Millipore: Percentage of residual kinase activity of CLK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720114 | Millipore: Percentage of residual kinase activity of DDR2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID266507 | Inhibition of starfish CDK1/cyclin B in presence of 15 uM ATP | 2006 | Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
| 3'-Substituted 7-halogenoindirubins, a new class of cell death inducing agents. |
| AID720230 | Millipore: Percentage of residual kinase activity of PLK3 at 1uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720484 | Millipore: Percentage of residual kinase activity of PRKCZ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID391487 | Inhibition of GSK3-mediated beta-casein phosphorylation in human SH-SY5Y cells in presence of MG132 by Western blot analysis | 2008 | Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
| Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period. |
| AID720026 | Millipore: Percentage of residual kinase activity of PRKAA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720148 | Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720259 | Millipore: Percentage of residual kinase activity of MAPK14 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720275 | Millipore: Percentage of residual kinase activity of SRPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720074 | Millipore: Percentage of residual kinase activity of CHEK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224762 | Delta TM value showing the stabilisation of CLK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720160 | Millipore: Percentage of residual kinase activity of FES at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720135 | Millipore: Percentage of residual kinase activity of EPHA8 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720183 | Millipore: Percentage of residual kinase activity of GSK3B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720452 | Millipore: Percentage of residual kinase activity of PAK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720235 | Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224791 | Delta TM value showing the stabilisation of PRKACA produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720278 | Millipore: Percentage of residual kinase activity of STK33 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720210 | Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720415 | Millipore: Percentage of residual kinase activity of WNK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720474 | Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224787 | Delta TM value showing the stabilisation of PIM2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720125 | Millipore: Percentage of residual kinase activity of EPHA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720267 | Millipore: Percentage of residual kinase activity of SGK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720394 | Millipore: Percentage of residual kinase activity of TSSK1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720371 | Millipore: Percentage of residual kinase activity of SRPK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224800 | Delta TM value showing the stabilisation of MST4 (2) produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720028 | Millipore: Percentage of residual kinase activity of NUAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720481 | Millipore: Percentage of residual kinase activity of PRKCD at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720242 | Millipore: Percentage of residual kinase activity of RET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID391480 | Inhibition of CDK1/cyclin B | 2008 | Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
| Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period. |
| AID500949 | Effect on gross morphology of heterozygous transgenic zebrafish embryo at 0.5 uM | 2009 | Nature chemical biology, Apr, Volume: 5, Issue:4
| Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. |
| AID1224773 | Delta TM value showing the stabilisation of ASK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720206 | Millipore: Percentage of residual kinase activity of PRKD1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720274 | Millipore: Percentage of residual kinase activity of SRPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1513679 | Inhibition of His-tagged CDK2/cyclin E (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay | 2018 | Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
| How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases? |
| AID720245 | Millipore: Percentage of residual kinase activity of MST1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720322 | Millipore: Percentage of residual kinase activity of MAPK10 at 1uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720073 | Millipore: Percentage of residual kinase activity of CHEK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224775 | Delta TM value showing the stabilisation of ERK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720082 | Millipore: Percentage of residual kinase activity of CSNK1G3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720096 | Millipore: Percentage of residual kinase activity of CAMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1139563 | Cytotoxicity against human monocytes assessed as viability at 10 uM after 4 hrs by MTT assay | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID720226 | Millipore: Percentage of residual kinase activity of PIM3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720078 | Millipore: Percentage of residual kinase activity of CSNK1G1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1513683 | Inhibition of GST-tagged CDK7/cyclinH/MAT1 (unknown origin) expressed in Baculovirus infected Sf9 cells using YSPTSPS-2 KK peptide as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay | 2018 | Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
| How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases? |
| AID1224781 | Delta TM value showing the stabilisation of PAK4 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID266509 | Inhibition of porcine brain GSK3alpha/beta | 2006 | Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
| 3'-Substituted 7-halogenoindirubins, a new class of cell death inducing agents. |
| AID720234 | Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720218 | Millipore: Percentage of residual kinase activity of FRK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720448 | Millipore: Percentage of residual kinase activity of PAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720469 | Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720465 | Millipore: Percentage of residual kinase activity of PRKACA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720308 | Millipore: Percentage of residual kinase activity of IRAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720359 | Millipore: Percentage of residual kinase activity of MYLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720398 | Millipore: Percentage of residual kinase activity of TEC at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720289 | Millipore: Percentage of residual kinase activity of TAOK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720049 | Millipore: Percentage of residual kinase activity of BMX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720094 | Millipore: Percentage of residual kinase activity of CSK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1895345 | Inhibition of GST-fused CDK5/p25 (unknown origin) | 2021 | European journal of medicinal chemistry, Nov-05, Volume: 223 | Anticancer potential of indirubins in medicinal chemistry: Biological activity, structural modification, and structure-activity relationship. |
| AID469493 | Inhibition of human CDK2/Cyclin A assessed as residual enzyme activity at 0.3 uM after 40 mins by scintillation counting | 2009 | Journal of natural products, Dec, Volume: 72, Issue:12
| Synthesis and antiproliferative activity of 7-azaindirubin-3'-oxime, a 7-aza isostere of the natural indirubin pharmacophore. |
| AID720233 | Millipore: Percentage of residual kinase activity of PRKX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1459310 | Inhibition of GSK3beta (unknown origin) | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Natural and synthetic bioactive inhibitors of glycogen synthase kinase. |
| AID720079 | Millipore: Percentage of residual kinase activity of CSNK1G2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1513680 | Inhibition of GST-tagged CDK4/cyclin D1 (unknown origin) expressed in Baculovirus infected Sf9 cells using RPPTLSPIPHIPR peptide as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay | 2018 | Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
| How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases? |
| AID720425 | Millipore: Percentage of residual kinase activity of RAF1 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720351 | Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720391 | Millipore: Percentage of residual kinase activity of NEK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720192 | Millipore: Percentage of residual kinase activity of GSG2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID532592 | Therapeutic index, ration of TD50 for human foreskin fibroblast cell infected with Toxoplasma gondii to ID 50 for Toxoplasma gondii | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
| Inhibition of Toxoplasma gondii by indirubin and tryptanthrin analogs. |
| AID1224771 | Delta TM value showing the stabilisation of MEK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224754 | Delta TM value showing the stabilisation of CAMK2G produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720443 | Millipore: Percentage of residual kinase activity of NLK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720257 | Millipore: Percentage of residual kinase activity of RPS6KA6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720075 | Millipore: Percentage of residual kinase activity of CHEK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720250 | Millipore: Percentage of residual kinase activity of RPS6KA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720104 | Millipore: Percentage of residual kinase activity of CAMK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID297163 | Inhibition of human recombinant aurora A kinase | 2007 | Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
| An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins. |
| AID1895349 | Inhibition of human recombinant GST-fused PDK1 expressed in Sf9 cells incubated for 30 mins in presence of [gamma-33P]ATP by scintillation counter analysis | 2021 | European journal of medicinal chemistry, Nov-05, Volume: 223 | Anticancer potential of indirubins in medicinal chemistry: Biological activity, structural modification, and structure-activity relationship. |
| AID720064 | Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720382 | Millipore: Percentage of residual kinase activity of MKNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720153 | Millipore: Percentage of residual kinase activity of FGFR3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID325592 | Inhibition of Cdk1/cyclin B | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720453 | Millipore: Percentage of residual kinase activity of PAK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID416794 | Activation of Wnt signaling pathway in HEK293 cells assessed as increase in beta-casein-mediated Tcf/Lef transcriptional activity after 24 hrs by dual luciferase reporter gene | 2009 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
| Novel small molecule activators of beta-catenin-mediated signaling pathway: structure-activity relationships of indirubins. |
| AID720343 | Millipore: Percentage of residual kinase activity of MAPKAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720154 | Millipore: Percentage of residual kinase activity of FGFR3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720084 | Millipore: Percentage of residual kinase activity of CSNK1D at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1448908 | Inhibition of human N-terminal GST-tagged Aurora B (M1 to S27 residues) expressed in sf9 cells at 1 uM using CDC25C-derived peptide as substrate by filter binding assay | 2017 | Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
| Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule. |
| AID1224803 | Delta TM value showing the stabilisation of PBK produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224761 | Delta TM value showing the stabilisation of CLK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720400 | Millipore: Percentage of residual kinase activity of TEK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720106 | Millipore: Percentage of residual kinase activity of CAMK1D at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720205 | Millipore: Percentage of residual kinase activity of PRKCI at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720024 | Millipore: Percentage of residual kinase activity of PRKAA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720219 | Millipore: Percentage of residual kinase activity of FRK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720418 | Millipore: Percentage of residual kinase activity of YES1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720146 | Millipore: Percentage of residual kinase activity of ERBB4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID469491 | Inhibition of human CDK1/Cyclin B assessed as residual enzyme activity at 0.3 uM after 40 mins by scintillation counting | 2009 | Journal of natural products, Dec, Volume: 72, Issue:12
| Synthesis and antiproliferative activity of 7-azaindirubin-3'-oxime, a 7-aza isostere of the natural indirubin pharmacophore. |
| AID1139558 | Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID325615 | Inhibition of Cdk4/cyclin D1 | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720088 | Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720479 | Millipore: Percentage of residual kinase activity of PRKCG at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720426 | Millipore: Percentage of residual kinase activity of KIT at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720181 | Millipore: Percentage of residual kinase activity of GSK3A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720054 | Millipore: Percentage of residual kinase activity of BRSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720159 | Millipore: Percentage of residual kinase activity of FES at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720381 | Millipore: Percentage of residual kinase activity of MET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720121 | Millipore: Percentage of residual kinase activity of EGFR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720407 | Millipore: Percentage of residual kinase activity of TXK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720411 | Millipore: Percentage of residual kinase activity of ULK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224769 | Delta TM value showing the stabilisation of GSK3B produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720249 | Millipore: Percentage of residual kinase activity of TYRO3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224770 | Delta TM value showing the stabilisation of JAK1~B produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720101 | Millipore: Percentage of residual kinase activity of CAMK2D at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720456 | Millipore: Percentage of residual kinase activity of PASK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720253 | Millipore: Percentage of residual kinase activity of RPS6KA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224807 | Delta TM value showing the stabilisation of YSK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720292 | Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720397 | Millipore: Percentage of residual kinase activity of TSSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720109 | Millipore: Percentage of residual kinase activity of DAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720320 | Millipore: Percentage of residual kinase activity of MAPK9 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720299 | Millipore: Percentage of residual kinase activity of CHUK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224804 | Delta TM value showing the stabilisation of VRK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720208 | Millipore: Percentage of residual kinase activity of PRKD2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224764 | Delta TM value showing the stabilisation of CK1G1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1448890 | Inhibition of recombinant human N-terminal GST/His6-tagged CDK1 (M1 to M297 residues)/Cyclin B1 (M1 to V433 residues) expressed in sf9 cells at 1 uM using RB-CTF as substrate by filter binding assay | 2017 | Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
| Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule. |
| AID727164 | Inhibition of rat recombinant GST-fused DYRK1A expressed in Escherichia coli using KKISGRLSPIMTEQ as substrate after 30 mins by scintillation counting analysis in presence of [gamma-33P]-ATP | 2013 | ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
| Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases. |
| AID720417 | Millipore: Percentage of residual kinase activity of WNK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720383 | Millipore: Percentage of residual kinase activity of MKNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720140 | Millipore: Percentage of residual kinase activity of EPHB2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720305 | Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720302 | Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720186 | Millipore: Percentage of residual kinase activity of HIPK1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720373 | Millipore: Percentage of residual kinase activity of STK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720172 | Millipore: Percentage of residual kinase activity of FYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720025 | Millipore: Percentage of residual kinase activity of PRKAA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID73205 | Inhibitory activity against GSK-3-alpha/beta from porcine brain | 2004 | Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
| Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. |
| AID325620 | Inhibition of IRTK | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720256 | Millipore: Percentage of residual kinase activity of RPS6KA6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720350 | Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720053 | Millipore: Percentage of residual kinase activity of BRSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720467 | Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720248 | Millipore: Percentage of residual kinase activity of TYRO3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720331 | Millipore: Percentage of residual kinase activity of STK10 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720386 | Millipore: Percentage of residual kinase activity of NEK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720036 | Millipore: Percentage of residual kinase activity of AURKA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720050 | Millipore: Percentage of residual kinase activity of BMX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720060 | Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720113 | Millipore: Percentage of residual kinase activity of DDR2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID469486 | Inhibition of CDK5 | 2009 | Journal of natural products, Dec, Volume: 72, Issue:12
| Synthesis and antiproliferative activity of 7-azaindirubin-3'-oxime, a 7-aza isostere of the natural indirubin pharmacophore. |
| AID720439 | Millipore: Percentage of residual kinase activity of NEK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224772 | Delta TM value showing the stabilisation of MAP2K6 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720387 | Millipore: Percentage of residual kinase activity of NEK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720265 | Millipore: Percentage of residual kinase activity of MAPK13 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720297 | Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720039 | Millipore: Percentage of residual kinase activity of AURKC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720145 | Millipore: Percentage of residual kinase activity of ERBB4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720241 | Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720033 | Millipore: Percentage of residual kinase activity of ABL2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720422 | Millipore: Percentage of residual kinase activity of DAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID755445 | Agonist activity at PXR (unknown origin) expressed in human HepG2 cells assessed as induction of CYP3A4 transactivation after 16 hrs by luciferase reporter gene assay | 2013 | Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
| Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery. |
| AID720202 | Millipore: Percentage of residual kinase activity of PRKCQ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720416 | Millipore: Percentage of residual kinase activity of WNK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720138 | Millipore: Percentage of residual kinase activity of EPHB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720309 | Millipore: Percentage of residual kinase activity of IRAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720151 | Millipore: Percentage of residual kinase activity of FGFR2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720080 | Millipore: Percentage of residual kinase activity of CSNK1G2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720344 | Millipore: Percentage of residual kinase activity of MAPKAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720102 | Millipore: Percentage of residual kinase activity of CAMK2D at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720246 | Millipore: Percentage of residual kinase activity of ROS1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720188 | Millipore: Percentage of residual kinase activity of HIPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720368 | Millipore: Percentage of residual kinase activity of RPS6KA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1895406 | Antitumor activity against human A2058 cells xenografted in BALB/c mouse assessed as reduction in tumour volume at 50 mg/kg per day, po administered via oral gavage treated every other day for 14 days relative to control | 2021 | European journal of medicinal chemistry, Nov-05, Volume: 223 | Anticancer potential of indirubins in medicinal chemistry: Biological activity, structural modification, and structure-activity relationship. |
| AID720272 | Millipore: Percentage of residual kinase activity of SIK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720169 | Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1139555 | Inhibition of 5-LO in human neutrophils assessed as product formation by cell-intact assay relative to control in presence of 20 uM A23187/AA ionophore | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID720385 | Millipore: Percentage of residual kinase activity of MUSK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID325619 | Inhibition of CK | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224806 | Delta TM value showing the stabilisation of VRK3 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID500944 | Inhibition of GSK-3-beta-mediated activation of beta-casein signaling in heat-stimulated heterozygous transgenic zebrafish embryo assessed as upregulation of MPO gene expression at 0.5 uM by in-situ hybridization analysis | 2009 | Nature chemical biology, Apr, Volume: 5, Issue:4
| Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. |
| AID720286 | Millipore: Percentage of residual kinase activity of TAOK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720294 | Millipore: Percentage of residual kinase activity of TGFBR1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720364 | Millipore: Percentage of residual kinase activity of CDC42BPB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1448893 | Inhibition of recombinant human N-terminal GST-tagged CDK4 (S4 to E303 residues)/Cyclin D1 (Q4 to I295 residues) expressed in sf9 cells at 1 uM using RB-CTF as substrate by filter binding assay | 2017 | Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
| Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule. |
| AID453303 | Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
| Synthesis and evaluation of functionalized isoindigos as antiproliferative agents. |
| AID720212 | Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720058 | Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720062 | Millipore: Percentage of residual kinase activity of CDK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720270 | Millipore: Percentage of residual kinase activity of SGK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720461 | Millipore: Percentage of residual kinase activity of PDGFRB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720083 | Millipore: Percentage of residual kinase activity of CSNK1D at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720127 | Millipore: Percentage of residual kinase activity of EPHA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID469488 | Inhibition of human GSK3-beta assessed as residual enzyme activity at 0.3 uM after 40 mins by scintillation counting | 2009 | Journal of natural products, Dec, Volume: 72, Issue:12
| Synthesis and antiproliferative activity of 7-azaindirubin-3'-oxime, a 7-aza isostere of the natural indirubin pharmacophore. |
| AID720211 | Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720041 | Millipore: Percentage of residual kinase activity of AXL at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID532590 | Cytotoxicity against human foreskin fibroblast cell infected with Toxoplasma gondii | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
| Inhibition of Toxoplasma gondii by indirubin and tryptanthrin analogs. |
| AID720123 | Millipore: Percentage of residual kinase activity of EPHA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1157303 | Inhibition of GSK3 (unknown origin) assessed as inhibition of phosphate incorporation into substrate in presence of radiolabeled ATP | 2014 | Journal of natural products, May-23, Volume: 77, Issue:5
| Acridone alkaloids from Glycosmis chlorosperma as DYRK1A inhibitors. |
| AID1356875 | Protection against cisplatin-induced cell death in neonatal mouse HEI-OC1 cells assessed as reduction in caspase-3/7 activity | 2018 | Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
| Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss. |
| AID1224777 | Delta TM value showing the stabilisation of MST4(1) produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720428 | Millipore: Percentage of residual kinase activity of SRC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720034 | Millipore: Percentage of residual kinase activity of ABL2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720137 | Millipore: Percentage of residual kinase activity of EPHB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720232 | Millipore: Percentage of residual kinase activity of PRKX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224789 | Delta TM value showing the stabilisation of PLK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID325849 | Binding affinity to GSK3alpha | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID524795 | Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay | 2009 | Nature chemical biology, Oct, Volume: 5, Issue:10
| Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. |
| AID720282 | Millipore: Percentage of residual kinase activity of SYK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID500946 | Inhibition of GSK-3-beta-mediated activation of beta-casein signaling in heterozygous transgenic zebrafish embryo assessed as effect on MPO gene expression at 0.5 uM by in-situ hybridization analysis | 2009 | Nature chemical biology, Apr, Volume: 5, Issue:4
| Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. |
| AID720372 | Millipore: Percentage of residual kinase activity of STK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID727165 | Inhibition of porcine brain CK1 using RRKHAAIGpSAYSITA as substrate | 2013 | ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
| Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases. |
| AID720197 | Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1673317 | Induction of cellularization in human primary myotube assessed as beta-actin level at 5 uM in presence of reversine incubated for 72 hrs by Western blot analysis (Rvb = 1.095 No_unit) | 2019 | Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
| A novel indirubin derivative that increases somatic cell plasticity and inhibits tumorigenicity. |
| AID720366 | Millipore: Percentage of residual kinase activity of RPS6KA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720346 | Millipore: Percentage of residual kinase activity of MARK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720156 | Millipore: Percentage of residual kinase activity of FGFR4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720023 | Millipore: Percentage of residual kinase activity of PRKAA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720470 | Millipore: Percentage of residual kinase activity of AKT3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720051 | Millipore: Percentage of residual kinase activity of BRSK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720412 | Millipore: Percentage of residual kinase activity of VRK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720445 | Millipore: Percentage of residual kinase activity of PAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720086 | Millipore: Percentage of residual kinase activity of CSNK2A1 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224802 | Delta TM value showing the stabilisation of TNIK produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224780 | Delta TM value showing the stabilisation of OSR1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720328 | Millipore: Percentage of residual kinase activity of STK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720396 | Millipore: Percentage of residual kinase activity of TSSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720204 | Millipore: Percentage of residual kinase activity of PRKCI at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID727163 | Inhibition of human recombinant GST-fused DYRK2 expressed in Escherichia coli using KKISGRLSPIMTEQ as substrate after 30 mins by scintillation counting analysis in presence of [gamma-33P]-ATP | 2013 | ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
| Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases. |
| AID720171 | Millipore: Percentage of residual kinase activity of FYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720376 | Millipore: Percentage of residual kinase activity of STK24 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720420 | Millipore: Percentage of residual kinase activity of ZAP70 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720392 | Millipore: Percentage of residual kinase activity of TLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720166 | Millipore: Percentage of residual kinase activity of FLT3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720342 | Millipore: Percentage of residual kinase activity of MAPKAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720276 | Millipore: Percentage of residual kinase activity of SRPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1448889 | Inhibition of human N-terminal GST/His6-tagged GSK3beta (M1 to T420 residues) expressed in baculovirus infected sf9 cells at 1 uM using RBER-IRStide as substrate by filter binding assay | 2017 | Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
| Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule. |
| AID720482 | Millipore: Percentage of residual kinase activity of PRKCE at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720089 | Millipore: Percentage of residual kinase activity of CLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720126 | Millipore: Percentage of residual kinase activity of EPHA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720352 | Millipore: Percentage of residual kinase activity of MINK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720438 | Millipore: Percentage of residual kinase activity of NEK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1139569 | Inhibition of human GSK3 activity in HEK293 cells containing the Wnt/beta-catenin activated reporter pSuperTOPFLASH (STF293 cells) at 0.5 to 1 uM by Wnt reporter gene assay | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID720047 | Millipore: Percentage of residual kinase activity of BLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1513682 | Inhibition of GST-tagged CDK5/p25 (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay | 2018 | Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
| How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases? |
| AID1157305 | Inhibition of CLK1 (unknown origin) assessed as inhibition of phosphate incorporation into substrate in presence of radiolabeled ATP | 2014 | Journal of natural products, May-23, Volume: 77, Issue:5
| Acridone alkaloids from Glycosmis chlorosperma as DYRK1A inhibitors. |
| AID720410 | Millipore: Percentage of residual kinase activity of ULK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720303 | Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720087 | Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720055 | Millipore: Percentage of residual kinase activity of CDK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720037 | Millipore: Percentage of residual kinase activity of AURKB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720147 | Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720463 | Millipore: Percentage of residual kinase activity of PDPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720459 | Millipore: Percentage of residual kinase activity of PDGFRA at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224794 | Delta TM value showing the stabilisation of RSK2b produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720042 | Millipore: Percentage of residual kinase activity of AXL at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720323 | Millipore: Percentage of residual kinase activity of MAPK10 at 10uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224797 | Delta TM value showing the stabilisation of MPSK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720430 | Millipore: Percentage of residual kinase activity of EEF2K at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720090 | Millipore: Percentage of residual kinase activity of CLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720200 | Millipore: Percentage of residual kinase activity of PRKCH at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720291 | Millipore: Percentage of residual kinase activity of TAOK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID524790 | Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay | 2009 | Nature chemical biology, Oct, Volume: 5, Issue:10
| Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. |
| AID1895288 | Inhibition of starfish oocyte CDK1/Cyclin B using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counter analysis | 2021 | European journal of medicinal chemistry, Nov-05, Volume: 223 | Anticancer potential of indirubins in medicinal chemistry: Biological activity, structural modification, and structure-activity relationship. |
| AID500943 | Inhibition of GSK-3-beta-mediated activation of beta-casein signaling in heat-stimulated heterozygous transgenic zebrafish embryo assessed as down-regulation of gata1 gene expression at 0.5 uM by in-situ hybridization analysis | 2009 | Nature chemical biology, Apr, Volume: 5, Issue:4
| Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. |
| AID720173 | Millipore: Percentage of residual kinase activity of GCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1895350 | Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition at 10 uM by crystal violet staining based assay relative to control | 2021 | European journal of medicinal chemistry, Nov-05, Volume: 223 | Anticancer potential of indirubins in medicinal chemistry: Biological activity, structural modification, and structure-activity relationship. |
| AID720228 | Millipore: Percentage of residual kinase activity of PLK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720099 | Millipore: Percentage of residual kinase activity of CAMK2G at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1139554 | Inhibition of 5-LO in human neutrophils assessed as product formation by cell-intact assay relative to control in presence of 2.5 uM A23187 ionophore | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID720399 | Millipore: Percentage of residual kinase activity of TEC at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720271 | Millipore: Percentage of residual kinase activity of SGK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720067 | Millipore: Percentage of residual kinase activity of CDK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720339 | Millipore: Percentage of residual kinase activity of MAPK3 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720277 | Millipore: Percentage of residual kinase activity of SRPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224792 | Delta TM value showing the stabilisation of RIOK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID453304 | Antiproliferative activity against human HuH7 cells after 72 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
| Synthesis and evaluation of functionalized isoindigos as antiproliferative agents. |
| AID720117 | Millipore: Percentage of residual kinase activity of STK17A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720223 | Millipore: Percentage of residual kinase activity of PIM1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720402 | Millipore: Percentage of residual kinase activity of NTRK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224748 | Delta TM value showing the stabilisation of AMPKA2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720217 | Millipore: Percentage of residual kinase activity of PKN2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720098 | Millipore: Percentage of residual kinase activity of CAMK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224776 | Delta TM value showing the stabilisation of ERK3 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720281 | Millipore: Percentage of residual kinase activity of PLK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720365 | Millipore: Percentage of residual kinase activity of CDC42BPB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1076091 | Inhibition of human recombinant GST-fused CLK1 expressed in Escherichia coli using GRSRSRSRSRSR as substrate | 2014 | Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
| Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors. |
| AID512487 | Inhibition of CDK1/cyclinB | 2004 | Trends in pharmacological sciences, Sep, Volume: 25, Issue:9
| Pharmacological inhibitors of glycogen synthase kinase 3. |
| AID755454 | Antagonist activity at human GTS-tagged FXR after 20 mins by TR-FRET assay | 2013 | Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
| Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery. |
| AID720324 | Millipore: Percentage of residual kinase activity of KDR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720414 | Millipore: Percentage of residual kinase activity of WNK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720178 | Millipore: Percentage of residual kinase activity of GRK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720295 | Millipore: Percentage of residual kinase activity of TGFBR1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720142 | Millipore: Percentage of residual kinase activity of EPHB3 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720115 | Millipore: Percentage of residual kinase activity of DMPK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720077 | Millipore: Percentage of residual kinase activity of CSNK1G1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720433 | Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720440 | Millipore: Percentage of residual kinase activity of NEK7 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID469496 | Inhibition of human CDK5/p35 assessed as residual enzyme activity at 3 uM after 40 mins by scintillation counting | 2009 | Journal of natural products, Dec, Volume: 72, Issue:12
| Synthesis and antiproliferative activity of 7-azaindirubin-3'-oxime, a 7-aza isostere of the natural indirubin pharmacophore. |
| AID720198 | Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID391481 | Inhibition of human recombinant CDK5/p25 expressed in Escherichia coli | 2008 | Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
| Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period. |
| AID720273 | Millipore: Percentage of residual kinase activity of SIK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720213 | Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720380 | Millipore: Percentage of residual kinase activity of MET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720355 | Millipore: Percentage of residual kinase activity of MAP2K6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID325559 | Inhibition of PKG | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720111 | Millipore: Percentage of residual kinase activity of DCLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1513744 | Induction of cell cycle arrest in human HCT116 cells assessed as accumulation at G2/M phase at 1.7 to 19.8 uM after 24 hrs by propidium iodide-staining based flow cytometry | 2018 | Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
| How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases? |
| AID720447 | Millipore: Percentage of residual kinase activity of PAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720031 | Millipore: Percentage of residual kinase activity of ABL1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720209 | Millipore: Percentage of residual kinase activity of PRKD2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID524796 | Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay | 2009 | Nature chemical biology, Oct, Volume: 5, Issue:10
| Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. |
| AID1224757 | Delta TM value showing the stabilisation of CDK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720141 | Millipore: Percentage of residual kinase activity of EPHB3 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720338 | Millipore: Percentage of residual kinase activity of MAPK3 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720327 | Millipore: Percentage of residual kinase activity of LIMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1461889 | Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 24 hrs by alamar blue assay | | | |
| AID1673316 | Induction of cellularization in human primary myotube assessed as alpha-tubulin level at 5 uM in presence of reversine incubated for 72 hrs by Western blot analysis (Rvb = 0.674 No_unit) | 2019 | Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
| A novel indirubin derivative that increases somatic cell plasticity and inhibits tumorigenicity. |
| AID1139553 | Inhibition of human recombinant 5-LO assessed as product formation by cell-free assay relative to control | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID720129 | Millipore: Percentage of residual kinase activity of EPHA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1139565 | Inhibition of ovine COX1 using arachidonic acid at 10 uM after 5 mins by HPLC analysis | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID720427 | Millipore: Percentage of residual kinase activity of KIT at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720348 | Millipore: Percentage of residual kinase activity of MAP2K1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-35 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720390 | Millipore: Percentage of residual kinase activity of NEK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1076095 | inhibition of human recombinant CDK5/p25 using histone H1 as substrate by scintillation counting in presence of [gamma-33P]ATP | 2014 | Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
| Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors. |
| AID720252 | Millipore: Percentage of residual kinase activity of RPS6KA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224782 | Delta TM value showing the stabilisation of PAK5 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720155 | Millipore: Percentage of residual kinase activity of FGFR4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720370 | Millipore: Percentage of residual kinase activity of SRPK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720070 | Millipore: Percentage of residual kinase activity of CDK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720215 | Millipore: Percentage of residual kinase activity of MAPKAPK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720108 | Millipore: Percentage of residual kinase activity of DAPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224799 | Delta TM value showing the stabilisation of NDR1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720239 | Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID391482 | Inhibition of pig GSK3alpha/beta | 2008 | Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
| Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period. |
| AID720251 | Millipore: Percentage of residual kinase activity of RPS6KA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720174 | Millipore: Percentage of residual kinase activity of GCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720152 | Millipore: Percentage of residual kinase activity of FGFR2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1448891 | Inhibition of recombinant human N-terminal GST-tagged CDK2 (M1 to L298 residues)/Cyclin A2 (M1 to L432 residues) expressed in baculovirus infected sf9 cells at 1 uM using Histone H1 as substrate by filter binding assay | 2017 | Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
| Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule. |
| AID720255 | Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224801 | Delta TM value showing the stabilisation of MST1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224778 | Delta TM value showing the stabilisation of NEK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID469489 | Inhibition of human GSK3-beta assessed as residual enzyme activity at 3 uM after 40 mins by scintillation counting | 2009 | Journal of natural products, Dec, Volume: 72, Issue:12
| Synthesis and antiproliferative activity of 7-azaindirubin-3'-oxime, a 7-aza isostere of the natural indirubin pharmacophore. |
| AID720236 | Millipore: Percentage of residual kinase activity of RIPK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID391486 | Cytotoxicity against human SH-SY5Y cells after 48 hrs by MTS reduction assay | 2008 | Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
| Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period. |
| AID1224785 | Delta TM value showing the stabilisation of PDK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1139568 | Inhibition of human recombinant soluble epoxide hydrolase assessed as conversion of 3-phenyl-cyano(6-methoxy-2-naphthalenyl)methyl ester-2-oxiraneacetic acid to fluorescent 6-methoxy-naphthaldehyde at 10 uM after 10 mins by fluorescence-based assay | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID720360 | Millipore: Percentage of residual kinase activity of MAP3K9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1139549 | Reversible inhibition of human recombinant 5-LO assessed as product formation at 1 to 10 uM by dilution assay | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID720480 | Millipore: Percentage of residual kinase activity of PRKCD at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720280 | Millipore: Percentage of residual kinase activity of PLK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID327159 | Activation of cyclophilin B gene expression in rat INS-1E cells at 1 uM after 24 hrs relative to control | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
| 9-cyano-1-azapaullone (cazpaullone), a glycogen synthase kinase-3 (GSK-3) inhibitor activating pancreatic beta cell protection and replication. |
| AID720431 | Millipore: Percentage of residual kinase activity of EEF2K at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720066 | Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1157299 | Inhibition of CDK5 (unknown origin) assessed as inhibition of phosphate incorporation into substrate in presence of radiolabeled ATP | 2014 | Journal of natural products, May-23, Volume: 77, Issue:5
| Acridone alkaloids from Glycosmis chlorosperma as DYRK1A inhibitors. |
| AID720124 | Millipore: Percentage of residual kinase activity of EPHA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720164 | Millipore: Percentage of residual kinase activity of FLT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720345 | Millipore: Percentage of residual kinase activity of MAPKAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720404 | Millipore: Percentage of residual kinase activity of NTRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224786 | Delta TM value showing the stabilisation of PIM1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720247 | Millipore: Percentage of residual kinase activity of ROS1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID500945 | Inhibition of GSK-3-beta-mediated activation of beta-casein signaling in heterozygous transgenic zebrafish embryo assessed as effect on gata1 gene expression at 0.5 uM by in-situ hybridization analysis | 2009 | Nature chemical biology, Apr, Volume: 5, Issue:4
| Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. |
| AID720119 | Millipore: Percentage of residual kinase activity of DYRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720189 | Millipore: Percentage of residual kinase activity of HIPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1367964 | Cytotoxicity against mouse HT22 cells at 20 uM after 24 hrs by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
| Indirubin derivatives protect against endoplasmic reticulum stress-induced cytotoxicity and down-regulate CHOP levels in HT22 cells. |
| AID720134 | Millipore: Percentage of residual kinase activity of EPHA7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720046 | Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720063 | Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720222 | Millipore: Percentage of residual kinase activity of PIM1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720131 | Millipore: Percentage of residual kinase activity of EPHA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720437 | Millipore: Percentage of residual kinase activity of RPS6KB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1139567 | Inhibition of human mPGES1 from human A549 cells assessed as PGE2 at 10 uM after 15 mins by HPLC | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID720434 | Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP12 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720446 | Millipore: Percentage of residual kinase activity of PAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1139559 | Reversible inhibition of human recombinant 5-LO assessed as product formation at 0.3 to 3 uM by dilution assay | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID327153 | Activation of Pax4 RNA expression in rat INS-1E cells at 1 uM after 24 hrs relative to control | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
| 9-cyano-1-azapaullone (cazpaullone), a glycogen synthase kinase-3 (GSK-3) inhibitor activating pancreatic beta cell protection and replication. |
| AID720316 | Millipore: Percentage of residual kinase activity of JAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720035 | Millipore: Percentage of residual kinase activity of AURKA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720310 | Millipore: Percentage of residual kinase activity of INSRR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1513678 | Inhibition of His-tagged CDK1/cyclin B1 (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay | 2018 | Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
| How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases? |
| AID720449 | Millipore: Percentage of residual kinase activity of PAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720436 | Millipore: Percentage of residual kinase activity of RPS6KB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720044 | Millipore: Percentage of residual kinase activity of PTK6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1076094 | Inhibition of GSK3 alpha/beta in pig brain using YRRAAVPPSPSLSRHSSPHQpSEDEEE as substrate by scintillation counting in presence of [gamma-33P]ATP | 2014 | Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
| Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors. |
| AID720268 | Millipore: Percentage of residual kinase activity of SGK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224805 | Delta TM value showing the stabilisation of VRK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720336 | Millipore: Percentage of residual kinase activity of LYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224758 | Delta TM value showing the stabilisation of CDK6 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1076092 | Inhibition of rat recombinant GST-fused DYRK1A expressed in Escherichia coli using KKISGRLSPIMTEQ as substrate by scintillation counting in presence of [gamma-33P]ATP | 2014 | Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
| Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors. |
| AID720326 | Millipore: Percentage of residual kinase activity of LIMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720118 | Millipore: Percentage of residual kinase activity of STK17A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720130 | Millipore: Percentage of residual kinase activity of EPHA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1139552 | Inhibition of 5-LO in human neutrophils assessed as product formation at 3 uM by cell-intact assay relative to control in presence of 2.5 uM A23187 ionophore | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID1356876 | Protection against cisplatin-induced toxicity in P3 mouse cochlear explants assessed as increase in outer hair cell count incubated for 24 hrs by phalloidin staining based confocal microscopy | 2018 | Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
| Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss. |
| AID720429 | Millipore: Percentage of residual kinase activity of SRC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720244 | Millipore: Percentage of residual kinase activity of MST1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1139571 | Antiinflammatory activity against human monocytes assessed as reduction of LPS-induced TNFalpha expression | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID1224788 | Delta TM value showing the stabilisation of PIM3 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720279 | Millipore: Percentage of residual kinase activity of STK33 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID727166 | Inhibition of porcine brain GSK3beta using YRRAAVPPSPSLSRHSSPHQSpEDEEE as substrate | 2013 | ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
| Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases. |
| AID720120 | Millipore: Percentage of residual kinase activity of DYRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720442 | Millipore: Percentage of residual kinase activity of NLK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720363 | Millipore: Percentage of residual kinase activity of CDC42BPA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720061 | Millipore: Percentage of residual kinase activity of CDK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720179 | Millipore: Percentage of residual kinase activity of GRK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720401 | Millipore: Percentage of residual kinase activity of TEK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID266511 | Survival of human SH-SY5Y cells after 24 hrs by MTS reduction assay | 2006 | Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
| 3'-Substituted 7-halogenoindirubins, a new class of cell death inducing agents. |
| AID325540 | Inhibition of PKA | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224784 | Delta TM value showing the stabilisation of PCTK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1513681 | Inhibition of GST-tagged CDK2/cyclin A2 (unknown origin) expressed in Escherichia coli using histone H1 as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay | 2018 | Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
| How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases? |
| AID720191 | Millipore: Percentage of residual kinase activity of GSG2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1139574 | Antiinflammatory activity against human monocytes assessed as reduction of LPS-induced IL-1beta expression | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID1224793 | Delta TM value showing the stabilisation of RSK2a produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720072 | Millipore: Percentage of residual kinase activity of CDK9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720347 | Millipore: Percentage of residual kinase activity of MARK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720237 | Millipore: Percentage of residual kinase activity of RIPK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720175 | Millipore: Percentage of residual kinase activity of GRK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720435 | Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP12 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720293 | Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224796 | Delta TM value showing the stabilisation of LOK produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720269 | Millipore: Percentage of residual kinase activity of SGK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID469492 | Inhibition of human CDK1/Cyclin B assessed as residual enzyme activity at 3 uM after 40 mins by scintillation counting | 2009 | Journal of natural products, Dec, Volume: 72, Issue:12
| Synthesis and antiproliferative activity of 7-azaindirubin-3'-oxime, a 7-aza isostere of the natural indirubin pharmacophore. |
| AID720112 | Millipore: Percentage of residual kinase activity of DCLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720201 | Millipore: Percentage of residual kinase activity of PRKCH at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1139573 | Antiinflammatory activity against human monocytes assessed as reduction of LPS-induced IL-8 expression | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID1448892 | Inhibition of recombinant human N-terminal GST-tagged CDK2 (M1 to L298 residues)/Cyclin E1 (M1 to A395 residues) expressed in sf9 cells at 1 uM using RB-CTF as substrate by filter binding assay | 2017 | Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
| Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule. |
| AID720460 | Millipore: Percentage of residual kinase activity of PDGFRB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720240 | Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720144 | Millipore: Percentage of residual kinase activity of EPHB4 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720059 | Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID524792 | Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay | 2009 | Nature chemical biology, Oct, Volume: 5, Issue:10
| Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. |
| AID1224795 | Delta TM value showing the stabilisation of SLK produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720335 | Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720133 | Millipore: Percentage of residual kinase activity of EPHA7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720116 | Millipore: Percentage of residual kinase activity of DMPK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1139562 | Inhibition of 5-LO in fMLP-stimulated human monocytes assessed as reduction in HETE formation | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID720421 | Millipore: Percentage of residual kinase activity of ZAP70 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720349 | Millipore: Percentage of residual kinase activity of MAP2K1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-35 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720032 | Millipore: Percentage of residual kinase activity of ABL1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720304 | Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1139564 | Cytotoxicity against human neutrophils assessed as viability at 10 uM after 4 hrs by MTT assay | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID1224750 | Delta TM value showing the stabilisation of CAMK1G produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1157304 | Inhibition of CK1 (unknown origin) assessed as inhibition of phosphate incorporation into substrate in presence of radiolabeled ATP | 2014 | Journal of natural products, May-23, Volume: 77, Issue:5
| Acridone alkaloids from Glycosmis chlorosperma as DYRK1A inhibitors. |
| AID720231 | Millipore: Percentage of residual kinase activity of PLK3 at 10uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720337 | Millipore: Percentage of residual kinase activity of LYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720068 | Millipore: Percentage of residual kinase activity of CDK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720122 | Millipore: Percentage of residual kinase activity of EGFR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720389 | Millipore: Percentage of residual kinase activity of NEK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID325541 | Inhibition of PKC | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720388 | Millipore: Percentage of residual kinase activity of NEK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID524794 | Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay | 2009 | Nature chemical biology, Oct, Volume: 5, Issue:10
| Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. |
| AID453302 | Antiproliferative activity against human HL60 cells after 5 days by MTT assay | 2009 | Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
| Synthesis and evaluation of functionalized isoindigos as antiproliferative agents. |
| AID720330 | Millipore: Percentage of residual kinase activity of STK10 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720477 | Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720158 | Millipore: Percentage of residual kinase activity of FER at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720361 | Millipore: Percentage of residual kinase activity of MAP3K9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720227 | Millipore: Percentage of residual kinase activity of PIM3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID453559 | Inhibition of CDK2/cyclin A at 10 uM by IMAP assay | 2009 | Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
| Synthesis and evaluation of functionalized isoindigos as antiproliferative agents. |
| AID720300 | Millipore: Percentage of residual kinase activity of IKBKB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720103 | Millipore: Percentage of residual kinase activity of CAMK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720056 | Millipore: Percentage of residual kinase activity of CDK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720027 | Millipore: Percentage of residual kinase activity of NUAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID606664 | Inhibition of human recombinant PKR autophosphorylation using poly[I:C] after 10 mins by luminescent assay | 2011 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
| Identification of new inhibitors of protein kinase R guided by statistical modeling. |
| AID1513684 | Inhibition of GST-tagged CDK9/CyclinT1 (unknown origin) expressed in Baculovirus infected Sf9 cells using YSPTSPS-2 KK peptide as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay | 2018 | Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
| How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases? |
| AID1459470 | Cytotoxicity against human KCL22 cells assessed as cell viability at 1 uM after 48 hrs by MTS assay relative to control | 2016 | Journal of natural products, 10-28, Volume: 79, Issue:10
| Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines. |
| AID1224759 | Delta TM value showing the stabilisation of CDKL1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720262 | Millipore: Percentage of residual kinase activity of MAPK12 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720290 | Millipore: Percentage of residual kinase activity of TAOK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720057 | Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1448907 | Inhibition of human N-terminal GST/His6-tagged Aurora B (A2 to A344 residues) expressed in sf9 cells at 1 uM using tetra(LRRLSLG) as substrate by filter binding assay | 2017 | Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
| Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule. |
| AID720180 | Millipore: Percentage of residual kinase activity of GRK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720184 | Millipore: Percentage of residual kinase activity of GSK3B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720384 | Millipore: Percentage of residual kinase activity of MUSK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224768 | Delta TM value showing the stabilisation of DMPK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720022 | Millipore: Percentage of residual kinase activity of ACVR1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID469485 | Inhibition of GSK3 | 2009 | Journal of natural products, Dec, Volume: 72, Issue:12
| Synthesis and antiproliferative activity of 7-azaindirubin-3'-oxime, a 7-aza isostere of the natural indirubin pharmacophore. |
| AID327152 | Activation of Pax4 RNA expression in rat INS-1E cells at 1 uM after 4 hrs relative to control | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
| 9-cyano-1-azapaullone (cazpaullone), a glycogen synthase kinase-3 (GSK-3) inhibitor activating pancreatic beta cell protection and replication. |
| AID266525 | Death of human SH-SY5Y cells in presence of 20 uM Q-VD-OPh by MTS reduction assay | 2006 | Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
| 3'-Substituted 7-halogenoindirubins, a new class of cell death inducing agents. |
| AID720377 | Millipore: Percentage of residual kinase activity of STK24 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720476 | Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1157300 | Inhibition of DYRK1A (unknown origin) assessed as inhibition of phosphate incorporation into substrate in presence of radiolabeled ATP | 2014 | Journal of natural products, May-23, Volume: 77, Issue:5
| Acridone alkaloids from Glycosmis chlorosperma as DYRK1A inhibitors. |
| AID720105 | Millipore: Percentage of residual kinase activity of CAMK1D at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224783 | Delta TM value showing the stabilisation of PAK6 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720020 | Millipore: Percentage of residual kinase activity of ALK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720340 | Millipore: Percentage of residual kinase activity of MAPK1 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1139557 | Binding affinity to human recombinant 5-LO ATP-bindng site using ATP-agaarose column in S40 fraction of Escherichia coli | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID469487 | Inhibition of human GSK3-beta assessed as residual enzyme activity at 0.01 uM after 40 mins by scintillation counting | 2009 | Journal of natural products, Dec, Volume: 72, Issue:12
| Synthesis and antiproliferative activity of 7-azaindirubin-3'-oxime, a 7-aza isostere of the natural indirubin pharmacophore. |
| AID532591 | Antimicrobial activity against Toxoplasma gondii | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
| Inhibition of Toxoplasma gondii by indirubin and tryptanthrin analogs. |
| AID297165 | Inhibition of human recombinant aurora C kinase | 2007 | Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
| An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins. |
| AID1139556 | Inhibition of pig brain GSK3 using YRRAAVPPSPSLSRHSSPHQSpEDEEE substrate by cell-free assay | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID524791 | Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay | 2009 | Nature chemical biology, Oct, Volume: 5, Issue:10
| Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. |
| AID720369 | Millipore: Percentage of residual kinase activity of RPS6KA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID755444 | Agonist activity at PXR (unknown origin) expressed in human HepG2 cells assessed as induction of CYP3A4 transactivation at 1.25 uM after 16 hrs by luciferase reporter gene assay | 2013 | Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
| Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery. |
| AID720378 | Millipore: Percentage of residual kinase activity of MERTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720419 | Millipore: Percentage of residual kinase activity of YES1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1895351 | Antitumor activity against mouse 4T1-Luc cells xenografted in BALB/c mouse assessed as decrease in lung metastasis at 1 mg/kg, iv measured after 8 days by dual-luciferase reporter assay | 2021 | European journal of medicinal chemistry, Nov-05, Volume: 223 | Anticancer potential of indirubins in medicinal chemistry: Biological activity, structural modification, and structure-activity relationship. |
| AID720462 | Millipore: Percentage of residual kinase activity of PDPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID325614 | Inhibition of Cdk5/p25 | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720374 | Millipore: Percentage of residual kinase activity of STK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720162 | Millipore: Percentage of residual kinase activity of FGR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID469495 | Inhibition of human CDK5/p35 assessed as residual enzyme activity at 0.3 uM after 40 mins by scintillation counting | 2009 | Journal of natural products, Dec, Volume: 72, Issue:12
| Synthesis and antiproliferative activity of 7-azaindirubin-3'-oxime, a 7-aza isostere of the natural indirubin pharmacophore. |
| AID720296 | Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720263 | Millipore: Percentage of residual kinase activity of MAPK12 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720018 | Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224767 | Delta TM value showing the stabilisation of DAPK3 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720229 | Millipore: Percentage of residual kinase activity of PLK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720207 | Millipore: Percentage of residual kinase activity of PRKD1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720045 | Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720132 | Millipore: Percentage of residual kinase activity of EPHA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720220 | Millipore: Percentage of residual kinase activity of PHKG2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720423 | Millipore: Percentage of residual kinase activity of DAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720358 | Millipore: Percentage of residual kinase activity of MYLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720311 | Millipore: Percentage of residual kinase activity of INSRR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224766 | Delta TM value showing the stabilisation of CK1G3 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720332 | Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224790 | Delta TM value showing the stabilisation of PLK4 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID512485 | Inhibition of GSK3 | 2004 | Trends in pharmacological sciences, Sep, Volume: 25, Issue:9
| Pharmacological inhibitors of glycogen synthase kinase 3. |
| AID720451 | Millipore: Percentage of residual kinase activity of PAK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224756 | Delta TM value showing the stabilisation of CAMKK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1157298 | Inhibition of CDK1 (unknown origin) assessed as inhibition of phosphate incorporation into substrate in presence of radiolabeled ATP | 2014 | Journal of natural products, May-23, Volume: 77, Issue:5
| Acridone alkaloids from Glycosmis chlorosperma as DYRK1A inhibitors. |
| AID720284 | Millipore: Percentage of residual kinase activity of MAP3K7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1139551 | Inhibition of human recombinant 5-LO assessed as product formation at 3 uM by cell-free assay relative to control | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID720185 | Millipore: Percentage of residual kinase activity of HIPK1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720017 | Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720038 | Millipore: Percentage of residual kinase activity of AURKB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720312 | Millipore: Percentage of residual kinase activity of ITK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720254 | Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720076 | Millipore: Percentage of residual kinase activity of CHEK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720472 | Millipore: Percentage of residual kinase activity of PRKCA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1139550 | Antioxidant activity assessed as DPPH radical scavenging activity at 10 nmol for 30 mins | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID1224763 | Delta TM value showing the stabilisation of CLK3 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID618246 | Cytotoxicity against human IMR32 cells assessed as cell viability after 48 hrs by MTT assay | 2011 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
| Synthesis of methoxy- and bromo-substituted indirubins and their activities on apoptosis induction in human neuroblastoma cells. |
| AID720081 | Millipore: Percentage of residual kinase activity of CSNK1G3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720071 | Millipore: Percentage of residual kinase activity of CDK9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720110 | Millipore: Percentage of residual kinase activity of DAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224752 | Delta TM value showing the stabilisation of CAMK2B produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1448894 | Inhibition of recombinant human N-terminal GST-tagged CDK5 (M1 to P292 residues)/p35NCK (M1 to R307 residues) expressed in baculovirus infected sf9 cells at 1 uM using RB-CTF as substrate by filter binding assay | 2017 | Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
| Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule. |
| AID720298 | Millipore: Percentage of residual kinase activity of CHUK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224753 | Delta TM value showing the stabilisation of CAMK2D produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720030 | Millipore: Percentage of residual kinase activity of MAP3K5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224779 | Delta TM value showing the stabilisation of NEK6 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720052 | Millipore: Percentage of residual kinase activity of BRSK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720095 | Millipore: Percentage of residual kinase activity of CAMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720325 | Millipore: Percentage of residual kinase activity of KDR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID469484 | Inhibition of CDK1 | 2009 | Journal of natural products, Dec, Volume: 72, Issue:12
| Synthesis and antiproliferative activity of 7-azaindirubin-3'-oxime, a 7-aza isostere of the natural indirubin pharmacophore. |
| AID720128 | Millipore: Percentage of residual kinase activity of EPHA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720466 | Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720195 | Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720450 | Millipore: Percentage of residual kinase activity of PAK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720405 | Millipore: Percentage of residual kinase activity of NTRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID453301 | Antiproliferative activity against human K562 cells after 72 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
| Synthesis and evaluation of functionalized isoindigos as antiproliferative agents. |
| AID720150 | Millipore: Percentage of residual kinase activity of FGFR1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720040 | Millipore: Percentage of residual kinase activity of AURKC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1459471 | Cytotoxicity against human KCL22 cells harboring ABL1 T315I mutant assessed as cell viability at 1 uM after 48 hrs by MTS assay relative to control | 2016 | Journal of natural products, 10-28, Volume: 79, Issue:10
| Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines. |
| AID720264 | Millipore: Percentage of residual kinase activity of MAPK13 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID416793 | Activation of Wnt signaling pathway in HEK293 cells assessed as increase in beta-casein-mediated Tcf/Lef transcriptional activity at 250 nM after 24 hrs by dual luciferase reporter gene assay relative to control | 2009 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
| Novel small molecule activators of beta-catenin-mediated signaling pathway: structure-activity relationships of indirubins. |
| AID720167 | Millipore: Percentage of residual kinase activity of FLT4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID755455 | Antagonist activity at human GTS-tagged FXR at 15 uM after 20 mins by TR-FRET assay | 2013 | Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
| Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery. |
| AID720097 | Millipore: Percentage of residual kinase activity of CAMK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720085 | Millipore: Percentage of residual kinase activity of CSNK2A1 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720287 | Millipore: Percentage of residual kinase activity of TAOK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720473 | Millipore: Percentage of residual kinase activity of PRKCA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720406 | Millipore: Percentage of residual kinase activity of TXK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720157 | Millipore: Percentage of residual kinase activity of FER at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1139561 | Inhibition of 5-LO in LPS-stimulated human neutrophils assessed as reduction in HETE formation | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID1224749 | Delta TM value showing the stabilisation of CAMK1D produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720288 | Millipore: Percentage of residual kinase activity of TAOK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720136 | Millipore: Percentage of residual kinase activity of EPHA8 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720457 | Millipore: Percentage of residual kinase activity of PASK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720307 | Millipore: Percentage of residual kinase activity of IRAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720170 | Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720319 | Millipore: Percentage of residual kinase activity of MAPK8 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720356 | Millipore: Percentage of residual kinase activity of MAP2K7 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720199 | Millipore: Percentage of residual kinase activity of PRKCZ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720187 | Millipore: Percentage of residual kinase activity of HIPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720043 | Millipore: Percentage of residual kinase activity of PTK6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID327158 | Activation of cyclophilin B gene expression in rat INS-1E cells at 1 uM after 4 hrs relative to control | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
| 9-cyano-1-azapaullone (cazpaullone), a glycogen synthase kinase-3 (GSK-3) inhibitor activating pancreatic beta cell protection and replication. |
| AID1139570 | Inhibition of human GSK3 activity in human monocytes assessed as induction of stabilization of beta-catenin at 1 uM by Western blot analysis | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID720021 | Millipore: Percentage of residual kinase activity of ACVR1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720455 | Millipore: Percentage of residual kinase activity of MARK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID325610 | Inhibition Cdk2/cyclin A | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1224765 | Delta TM value showing the stabilisation of CK1G2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720362 | Millipore: Percentage of residual kinase activity of CDC42BPA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224798 | Delta TM value showing the stabilisation of DRAK1 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720243 | Millipore: Percentage of residual kinase activity of RET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720306 | Millipore: Percentage of residual kinase activity of IRAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720464 | Millipore: Percentage of residual kinase activity of PRKACA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1448906 | Inhibition of human N-terminal GST/His6-tagged Aurora A (M1 to S403 residues) expressed in baculovirus infected sf9 cells at 1 uM using tetra(LRRLSLG) as substrate by filter binding assay | 2017 | Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
| Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule. |
| AID720413 | Millipore: Percentage of residual kinase activity of VRK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID618245 | Cytotoxicity against human SK-N-SH cells assessed as cell viability after 48 hrs by MTT assay | 2011 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
| Synthesis of methoxy- and bromo-substituted indirubins and their activities on apoptosis induction in human neuroblastoma cells. |
| AID1224760 | Delta TM value showing the stabilisation of CHEK2 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID469494 | Inhibition of human CDK2/Cyclin A assessed as residual enzyme activity at 3 uM after 40 mins by scintillation counting | 2009 | Journal of natural products, Dec, Volume: 72, Issue:12
| Synthesis and antiproliferative activity of 7-azaindirubin-3'-oxime, a 7-aza isostere of the natural indirubin pharmacophore. |
| AID720444 | Millipore: Percentage of residual kinase activity of PAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1139560 | Inhibition of 15-LO in human monocytes assessed as 12/15-HETE formation at 0.1 to 10 uM for 10 mins by UPLC-MS/MS analysis | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID266510 | Survival of human SH-SY5Y cells at 25 uM by MTS reduction assay | 2006 | Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
| 3'-Substituted 7-halogenoindirubins, a new class of cell death inducing agents. |
| AID720214 | Millipore: Percentage of residual kinase activity of MAPKAPK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720441 | Millipore: Percentage of residual kinase activity of NEK7 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720458 | Millipore: Percentage of residual kinase activity of PDGFRA at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720393 | Millipore: Percentage of residual kinase activity of TLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1448909 | Inhibition of CHK2 (unknown origin) at 1 uM | 2017 | Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
| Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule. |
| AID720203 | Millipore: Percentage of residual kinase activity of PRKCQ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720409 | Millipore: Percentage of residual kinase activity of ULK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720221 | Millipore: Percentage of residual kinase activity of PHKG2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1367965 | Cytoprotective activity against tunicamycin-induced cell death in mouse HT22 cells at 20 uM after 24 hrs by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
| Indirubin derivatives protect against endoplasmic reticulum stress-induced cytotoxicity and down-regulate CHOP levels in HT22 cells. |
| AID720424 | Millipore: Percentage of residual kinase activity of RAF1 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID453305 | Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
| Synthesis and evaluation of functionalized isoindigos as antiproliferative agents. |
| AID720065 | Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID266512 | Survival of human SH-SY5Y cells after 48 hrs by MTS reduction assay | 2006 | Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
| 3'-Substituted 7-halogenoindirubins, a new class of cell death inducing agents. |
| AID1895346 | Inhibition of porcine brain GSK-3alpha/beta incubated for 30 mins in presence of [33p]-gamma ATP by scintillation counter analysis | 2021 | European journal of medicinal chemistry, Nov-05, Volume: 223 | Anticancer potential of indirubins in medicinal chemistry: Biological activity, structural modification, and structure-activity relationship. |
| AID720165 | Millipore: Percentage of residual kinase activity of FLT3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1448910 | Inhibition of human N-terminal GST/His6-tagged FGFR1 (G400 to R820 residues) expressed in baculovirus infected sf9 cells at 1 uM using Poly(Glu,Tyr)4:1 as substrate by filter binding assay | 2017 | Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
| Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule. |
| AID720375 | Millipore: Percentage of residual kinase activity of STK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720471 | Millipore: Percentage of residual kinase activity of AKT3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720354 | Millipore: Percentage of residual kinase activity of MAP2K6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720315 | Millipore: Percentage of residual kinase activity of JAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720194 | Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720107 | Millipore: Percentage of residual kinase activity of DAPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1224755 | Delta TM value showing the stabilisation of CAMK4 produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID1076093 | Inhibition of CK1 delta/epsilon in pig brain using RRKHAAIGpSAYSITA as substrate by scintillation counting in presence of [gamma-33P]ATP | 2014 | Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
| Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors. |
| AID720190 | Millipore: Percentage of residual kinase activity of HIPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720329 | Millipore: Percentage of residual kinase activity of STK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID391483 | Solubility in water | 2008 | Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
| Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period. |
| AID1224774 | Delta TM value showing the stabilisation of p38beta produced by compound binding | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
| AID720260 | Millipore: Percentage of residual kinase activity of MAPK11 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720333 | Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720314 | Millipore: Percentage of residual kinase activity of JAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID266508 | Inhibition of mammalian CDK5/p25 | 2006 | Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
| 3'-Substituted 7-halogenoindirubins, a new class of cell death inducing agents. |
| AID720341 | Millipore: Percentage of residual kinase activity of MAPK1 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720177 | Millipore: Percentage of residual kinase activity of GRK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720149 | Millipore: Percentage of residual kinase activity of FGFR1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720321 | Millipore: Percentage of residual kinase activity of MAPK9 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720432 | Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720100 | Millipore: Percentage of residual kinase activity of CAMK2G at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID266513 | Death of human SH-SY5Y cells at 25 uM after 48 hrs by LDH release assay | 2006 | Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
| 3'-Substituted 7-halogenoindirubins, a new class of cell death inducing agents. |
| AID720139 | Millipore: Percentage of residual kinase activity of EPHB2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720283 | Millipore: Percentage of residual kinase activity of SYK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID54177 | Inhibitory activity against Cyclin-dependent kinase 5-p35nck5a | 2004 | Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
| Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. |
| AID720216 | Millipore: Percentage of residual kinase activity of PKN2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720353 | Millipore: Percentage of residual kinase activity of MINK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1139572 | Antiinflammatory activity against human monocytes assessed as reduction of LPS-induced IL-6 expression | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
| Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. |
| AID720143 | Millipore: Percentage of residual kinase activity of EPHB4 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID55517 | Inhibitory activity against cyclin dependent kinase 1-cyclinB from starfish (Marthasterias glacialis) oocytes | 2004 | Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
| Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. |
| AID720168 | Millipore: Percentage of residual kinase activity of FLT4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720196 | Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720408 | Millipore: Percentage of residual kinase activity of ULK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720224 | Millipore: Percentage of residual kinase activity of PIM2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID297164 | Inhibition of human recombinant aurora B kinase | 2007 | Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
| An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins. |
| AID720313 | Millipore: Percentage of residual kinase activity of ITK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720266 | Millipore: Percentage of residual kinase activity of SGK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720029 | Millipore: Percentage of residual kinase activity of MAP3K5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720261 | Millipore: Percentage of residual kinase activity of MAPK11 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID391485 | Lipophilicity, log D of the compound | 2008 | Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
| Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period. |
| AID720403 | Millipore: Percentage of residual kinase activity of NTRK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720092 | Millipore: Percentage of residual kinase activity of CLK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720317 | Millipore: Percentage of residual kinase activity of JAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720019 | Millipore: Percentage of residual kinase activity of ALK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720468 | Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720483 | Millipore: Percentage of residual kinase activity of PRKCE at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720454 | Millipore: Percentage of residual kinase activity of MARK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720225 | Millipore: Percentage of residual kinase activity of PIM2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720301 | Millipore: Percentage of residual kinase activity of IKBKB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720285 | Millipore: Percentage of residual kinase activity of MAP3K7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720478 | Millipore: Percentage of residual kinase activity of PRKCG at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720193 | Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID720379 | Millipore: Percentage of residual kinase activity of MERTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1603725 | Inhibition of recombinant human 5-LOX using Arachidonic acid as substrate by H2DCFD dye based fluorescence method | 2019 | Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
| 5-Lipoxygenase as a drug target: A review on trends in inhibitors structural design, SAR and mechanism based approach. |
| AID1347049 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500
| Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1347405 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID588349 | qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay | | | |
| AID1347050 | Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500
| Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID588378 | qHTS for Inhibitors of ATXN expression: Validation | | | |
| AID1347058 | CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7
| Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347045 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500
| Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1347057 | CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7
| Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347059 | CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7
| Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347151 | Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID504836 | Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation | 2002 | The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
| Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. |
| AID1347410 | qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library | 2019 | Cellular signalling, 08, Volume: 60 | A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening. |
| AID686947 | qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
| Identification of potent Yes1 kinase inhibitors using a library screening approach. |
| AID1347412 | qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1065837 | Inhibition of GSK-3beta (unknown origin) using (RREGGMSRPAS(p)VDG as substrate assessed as 32P[gamma-ATP] incorporation into substrate after 15 mins by autoradiography | 2013 | Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
| Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3β inhibitors. |
| AID1345677 | Human cyclin dependent kinase 5 (CDK5 subfamily) | 2004 | Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
| Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. |
| AID1345677 | Human cyclin dependent kinase 5 (CDK5 subfamily) | 2003 | Chemistry & biology, Dec, Volume: 10, Issue:12
| GSK-3-selective inhibitors derived from Tyrian purple indirubins. |
| AID707269 | Inhibition of GSK3-mediated beta casein phosphorylation in mouse HT22 cells at 10 uM after 24 hrs by Western blot analysis in presence of MG132 | 2012 | Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
| Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |